Swiss

RAAAM Memory Technologies Closes $4M Seed Round to Commercialize Super Cost Effective On-Chip Memory Solutions

Retrieved on: 
Monday, April 15, 2024
Technology, Hardware, Semiconductor, Bar-Ilan University, SRAM, Doctor of Philosophy, SOC, CMOS, Fin field-effect transistor, Silicon, Research, Artificial intelligence, EPFL, VLSI, Machine learning, CIO, FD-SOI, Swiss

RAAAM Memory Technologies, a start-up company that invented a groundbreaking solution to implement on-chip memory, announced today that it has completed a Seed financing round of $4 million.

Key Points: 
  • RAAAM Memory Technologies, a start-up company that invented a groundbreaking solution to implement on-chip memory, announced today that it has completed a Seed financing round of $4 million.
  • Investors include Serpentine Ventures, J-Ventures, HackCapital, Silicon Catalyst Angels, Claves Investments and large multi-national semiconductor company as a strategic investor.
  • However, the industry standard Static Random Access Memory (SRAM) technology is very area-inefficient and has been facing major scaling difficulties in modern process technologies below 10nm.
  • “RAAAM’s Gain-Cell Random Access Memory (GCRAM) technology is a unique on-chip memory solution that only requires 3 transistors to store a bit of data, as opposed to 6-8 transistors needed for the existing SRAM-based highest-density memory technology.

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

Retrieved on: 
Wednesday, April 3, 2024
Annual report, Disclosure, Swiss, SIX Swiss Exchange, DAH, Security, Cryptocurrency

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH1260041939) from SIX Swiss Exchange and has exempted the company from certain obligations associated with the maintenance of the listing.
  • The last trading day of the company's shares on SIX Swiss Exchange will be on Friday, May 3, 2024 and the delisting will be effective as from Monday, May 6, 2024.
  • 2.01 Directive Regular Reporting Obligations [DRRO]);
    Publication of ad hoc announcements (Art.
  • 52 LR);
    Fulfilment of all regular reporting obligations (Art.

Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Nature Chemical Biology, General partnership, Drug development, Growth, Drug discovery, Macrocycle, Swiss, Seed, EPFL, Patient, Medicine, Nature Communications, CBO, Pharmaceutical industry

The funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls ‘nCycles’.

Key Points: 
  • The funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls ‘nCycles’.
  • nCycles are systematically designed by Orbis’ nGen1 platform to be orally bioavailable and membrane permeable, solving decades-long challenges in macrocycle drug design.
  • It’s a milestone for drug development,” said Morten Døssing, Chair of the Orbis Board and Partner at Novo Holdings.
  • Additionally, research recently published in Nature Chemical Biology demonstrates nGen’s ability to deliver nCycles that are orally bioavailable, marking a new era for macrocycle drug discovery.

Managing the transition to central bank digital currency

Retrieved on: 
Wednesday, February 14, 2024
Technical report, Regulation, Private sector, Aircraft, Interest, RTD, Policy, CES, Research Papers in Economics, A.2, The Economic Journal, RTK, International Settlement, F30, Next, A.6, Community business development corporation, A.7, UIP, American Economic Journal, National bank, Paper, Bank, Macroeconomics, Economy, Central bank, GSS, Capital, XF, Elasticity, Government, Competition, Credit, Social science, Volatility, Domestic, European, IH, Investment, A.13, SSRN, Intermediate, A.5, Section 2, AP, Probability, Review of Economic Dynamics, Foreign, Journal of Monetary Economics, Remuneration, Uncertainty, Medical classification, Bank of England, Shock, DF, Bank of Canada, ISSN, CIA, European Central Bank, Survival, RD, FH, KT, N B, Cuore, Monetary economics, Section 3, Welfare, Iteration, DSGE, Blessthefall, Reserve, Website, GBP, Calibration, RDC, Parameter, DCT, GDP, KF, Sokol, Rebelo, Figure, De Nederlandsche Bank, Parity, TFP, Depreciation, Total, BIS, Home, Section 4, Attitude, Acquisition, JEL, Cross, Household, FF, QT, Control, Swiss, Motion, ECB, M. A, GF, A.9, RT, Cattolica, Exercise, C.2, XH, Tax, Crowding, European Parliament, Literature, Reproduction, Political economy, Committee, Exp, E50, Uhlig, EUR, IID, Digital currency, Tourism, American Economic Review, Manuscript, AG, A.8, Research, F41, Friction, Public sector, PDF, U N, YH, Cryptocurrency
Key Points: 

    AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

    Retrieved on: 
    Friday, December 1, 2023
    AC, Medicine, EPFL, Boehringer Ingelheim, CFO, Acquisition, Vaccine, Doctor of Philosophy, Therapy, Interim management, Interim, CSO, EUR, Lancaster University, Swiss

    Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition.

    Key Points: 
    • Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition.
    • Dr. Madiha Derouazi, an accomplished immunologist, joins from Speransa Therapeutics where she had been CEO since inception in 2021, leading development of a novel platform of prophylactic vaccines.
    • Christopher Roberts joined AC Immune in 2019 and has served as Vice President, Finance and Interim CFO of AC Immune since 2022.
    • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “I am delighted to welcome Madiha Derouazi as our new CSO and to confirm Chris as CFO.

    New Publication: Scientists from National Institute on Aging, Amazentis and EPFL Publish Landmark Paper on an Essential Biological Pathway for Healthy Aging

    Retrieved on: 
    Thursday, December 7, 2023
    Nutrition, NIA, Immunity, Research, Immune system, Ageing, Disease, Mitophagy, Urolithin A, Pac-Man, National Institute on Aging, Health, Swiss, Cognition, Mitochondrion, Human, EPFL, Facial muscles, Cell, Inflammation, Vaccine, Dietary supplement, Brain, Nature Metabolism

    LAUSANNE, Switzerland, Dec. 7, 2023 /PRNewswire/ -- Timeline Nutrition announces the publication of a landmark scientific paper in Nature Metabolism, "Mitophagy in human health, aging and disease," a collaboration from the head of the National Institute on Aging (NIA), Prof. Luigi Ferrucci, and the Amazentis research team, led by Dr. Davide D'Amico. The review is coauthored by Professor Johan Auwerx from the prestigious Swiss Federal Institute of Technology (EPFL), Dr. Julie Faitg and Professor Anna Picca. 

    Key Points: 
    • The review is coauthored by Professor Johan Auwerx from the prestigious Swiss Federal Institute of Technology (EPFL), Dr. Julie Faitg and Professor Anna Picca.
    • With aging often comes a lack of energy, but what if it was the other way around?
    • Impaired mitophagy can lead to chronic, low-grade inflammation and weakened immune response in the elderly, a condition known as "inflammaging."
    • To learn more about Mitopure (Urolithin A) and how Timeline Nutrition is using these insights to develop innovative nutritional products, visit www.timelinenutrition.com .

    Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease

    Retrieved on: 
    Monday, November 6, 2023
    Euronext, The Michael J. Fox Foundation, Medical research, Swiss Federal Institute of Aquatic Science and Technology, MJFF, Teaching hospital, Clinical research, SCI, Research, INSERM, CHUV, Rehabilitation, Parkinson's disease, EPFL, Spinal cord, Swiss, ARC, Movement, Patient, Pharmaceutical industry, Medical device, Electric light, Nature Medicine

    The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.

    Key Points: 
    • The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.
    • The team collaborated with Dr. Erwan Bezard, a renowned neuroscientist from France’s National Institute of Health and Medical Research (INSERM).
    • Fox Foundation for Parkinson’s Research (MJFF) to implant the ARC-IM System and investigate the effect of ARC Therapy in six additional participants with Parkinson’s disease.
    • This study will assist ONWARD in determining whether to conduct additional clinical trials and potentially commercialize ARC Therapy in the future for those living with Parkinson’s disease.

    Safer and more Effective Brain Interfaces: First in Human Brain Recordings Achieved by Neurosoft Bioelectronics

    Retrieved on: 
    Tuesday, October 3, 2023
    Oncology, Health, Medical Devices, Neurology, Health Technology, Clinical Trials, Biotechnology, Epilepsy, Swiss, Swiss Federal Institute of Technology, Digital Writing and Research Lab, Tinnitus, Deafness, Auditory cortex, Brain, Multimedia, Research, Biomarker, Trial of the century, Paralysis, DSM-IV codes, Wyss Center for Bio and Neuroengineering, Electrode, Patient, Traumatic brain injury, Memorial Hermann Health System, Hematoma, EPFL, FDA, Swiss Federal Institute of Aquatic Science and Technology, Safety, Hippocampus, Medical imaging, Medical device, Nursing

    Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.

    Key Points: 
    • Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.
    • Furthermore, the application of Neurosoft Bioelectronics’ electrodes presents the possibility of uncovering supplementary biomarkers which could significantly help in providing more effective and safer treatments of brain disorders for future patients.
    • Amidst these challenges, Neurosoft Bioelectronics' soft and elastic electrodes present themselves as a promising alternative to existing invasive solutions.
    • The Neurosoft Bioelectronics team has also been studying how these electrodes could address indications like severe tinnitus.

    Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

    Retrieved on: 
    Thursday, September 28, 2023
    Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute for Materials Research and Testing, Pharmaceutical industry, Fine chemical, Nursing, Spexy Beast

    Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

    Key Points: 
    • Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
      Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
      Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
    • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
    • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
    • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

    Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

    Retrieved on: 
    Thursday, September 28, 2023
    Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute of Science and Technology, Fine chemical, Pharmaceutical industry, Nursing, Spexy Beast

    ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.

    Key Points: 
    • ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
    • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
    • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
    • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.